Earnings Call · Q1 FY2023·2023-02-07

Q1 23EPS +13.13%·Rev n/aQ4 22EPS +5.93%·Rev n/aQ3 22EPS -10.07%·Rev n/aQ2 22EPS -15.60%·Rev n/a⚠ consensus missing

ENANTA PHARMACEUTICALS INC ENTA

Jennifer Viera — Investor Relations or Corporate Communications

Jay Luly — President and Chief Executive Officer

Paul Mellett — Chief Financial Officer

−3.5%1d on move date−2.4% vs SPY3d−2.8%5d−8.8%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ENTA calls or request research access.

More ENTA calls Browse calls Request research access